Clinical Trials

Plasma cell

Multiple Myeloma

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Carcinoma, Transitional Cell

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05904704 2025-11-14

Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors

Phase NA Withdrawn

Brain Neoplasms

NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Central Nervous System Neoplasms

NCT04910425 2025-10-21

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Prostatic Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05483023 2025-10-14

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Gynecologic

Endometrial Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Colorectal Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Prostatic Neoplasms

NCT06670976 2025-08-26

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Sarcoma

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Dermatologic

Melanoma

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Breast

Triple Negative Breast Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05600556 2025-05-15

Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)

Phase NA Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT06390657 2025-05-11

S-C-PATHY

Withdrawn

Neoplasms

NCT03581500 2025-04-23

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Prostatic Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Neoplasms

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Neoplasm Metastasis

NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Glioblastoma

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04580836 2024-10-26

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial

Carcinoma, Renal Cell

NCT06427369 2024-09-27

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04023240 2024-08-12

68-Ga-FAPI PET Imaging in Malignancy

Neoplasms

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Neoplasms

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Phase 1/2 Withdrawn

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Prostatic Neoplasms

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT06137651 2024-04-01

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT04140513 2024-03-08

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Phase NA Withdrawn

Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Phase EARLY_PHASE1 Withdrawn

Prostatic Neoplasms

NCT05111314 2023-11-07

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Phase EARLY_PHASE1 Withdrawn

Carcinoma, Hepatocellular

NCT05728372 2023-10-10

64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation

Neoplasm Metastasis

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Gynecologic

Platinum-Refractory Fallopian Tube Carcinoma

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Phase 1/2 Withdrawn

Dermatologic

Uveal Melanoma

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Carcinoma, Non-Small-Cell Lung

NCT04483414 2023-05-19

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Prostatic Neoplasms

NCT04605614 2022-06-09

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Other hematologic neoplasm

Hematologic Neoplasms

NCT03234309 2021-11-10

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

Phase EARLY_PHASE1 Withdrawn

Brain Neoplasms

NCT02857218 2021-09-16

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer

Esophageal Neoplasms

NCT02919332 2020-07-24

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Withdrawn

Glioblastoma, Glioma

NCT03506802 2020-07-24

NYSCT MM